News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bioventus Expands To Mexico With DUROLANE For Knee Osteoarthritis Patients



11/14/2016 10:38:06 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

HOOFDDORP, The Netherlands--(BUSINESS WIRE)--Bioventus, a leader in orthobiologic solutions, has entered the patient care market in Mexico. This announcement reflects the company’s continued growth in international markets and its mission to partner with the health care community to help people resume and enjoy active lives. The initial Bioventus product available in Mexico is DUROLANE a single-injection joint-fluid therapy based on a natural, safe and proven technology called NASHA® which yields stabilized hyaluronic acid (HA). Hyaluronic acid is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint. In Mexico, DUROLANE is indicated for the symptomatic treatment of mild to moderate knee osteoarthritis (OA).

“It will be sold through Artimedica SA, a Mexican-based company that specializes in the sale and distribution of diagnostic, surgical and other healthcare products for hospitals and clinics across Mexico. We look forward to working with them to introduce this innovative single-injection solution to OA patients throughout the region.”

“International expansion is a key part of our growth strategy at Bioventus and launching in Mexico gives us greater access in Latin America which has tremendous potential for us,” said Tony Bihl, CEO, Bioventus. “We now have orthobiologic solutions in more than 29 countries and expect to expand our global sales and marketing footprint even more in the months to come.”

DUROLANE gives patients suffering from knee osteoarthritis another option for pain management,” said Isabelle Levy-Unger, Managing Director International, for Canada, Latin America and Asia Pacific, Bioventus. “It will be sold through Artimedica SA, a Mexican-based company that specializes in the sale and distribution of diagnostic, surgical and other healthcare products for hospitals and clinics across Mexico. We look forward to working with them to introduce this innovative single-injection solution to OA patients throughout the region.”

“We are very excited to market DUROLANE in Mexico,” said Arnulfo Salazar Guerra, Legal Representative for Artimedica. “Its technology offers clear benefits for the estimated 6.7 million Mexican patients that suffer from knee osteoarthritis.”

DUROLANE is available in Mexico now and is part of the Bioventus Active Healing Therapies portfolio which consists of products that allow patients to resume active lives using their bodies own processes to heal faster or reduce pain. More information is available at www.durolane.com.

About Bioventus

Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical, that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.

For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal.

DUROLANE - Indications

For the symptomatic treatment of mild to moderate knee osteoarthritis.

There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site. Clinical effectiveness has been demonstrated out to six months but results may vary depending on various patient factors.

NASHA is a registered trademark of Galderma S.A.

Bioventus, the Bioventus logo and DUROLANE are registered trademarks of Bioventus LLC.

Contacts

Media Contacts:
Bioventus
Thomas Hill
+1 919-474-6715
thomas.hill@bioventusglobal.com


Read at BioSpace.com


comments powered by Disqus
Bioventus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES